Navigation Links
Improved diagnostic performance of low-dose computed tomography screening
Date:6/15/2014

DENVER - Investigators of the COSMOS (Continuous Observation of SMOking Subjects) study show good compliance and patient survival outcomes using a 5-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer. This protocol had fewer patients requiring further diagnostic follow-up compared to other studies, including the National Lung Cancer Screening Trial (NLST), with a minimal number of incorrect diagnoses.

The 5-year survival rate for early diagnosed lung cancer is 50% but after the cancer has spread to distant regions it is only 4%. Recently, the NLST showed a 20% lung cancer mortality reduction with LDCT compared to chest x-ray, which verified that early detection can decrease lung cancer deaths. However, few studies have rigorously assessed the diagnostic performance, invasiveness and side effects of LDCT screening protocols with enduring follow-up.

The COSMOS study screened 5203 asymptomatic high-risk subjects (age ≥50 and ≥20 pack years smoking history) who, based on the study criteria, either went on to other diagnostic procedures (CT, PET, or surgery) to verify lung cancer, or were rescreened every year for the next 4 years. All subjects were clinically followed for a median of 5.2 years.

The results of this study, reported in the July issue of the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, show that overall, 79% of the participants remained on the study for 5 years and only 6.4% required a procedure beyond the annual LDCT. Primary lung cancer was diagnosed in 175 patients and 78% of these were diagnosed with localized disease. Due to the size and long follow-up, there were 23,116 person-years of observation. Therefore, the overall lung cancer detection rate was 0.76 per 100 person-years. Out of the 204 invasive diagnostic procedures, 29 were benign for lung cancer, 34 had minor complications, 12 major complications and 1 post-operative fatality was reported. There were 14 cases where the lesions were not diagnosed as cancer, but were later determined to be cancer on subsequent yearly screening. A high proportion of the cancers (87%) were treated with intent to cure and the overall 5-years survival was 78%.

"The results of the COSMOS workup protocol for indeterminate nodules detected with LDCT screening are encouraging, particularly the low recall and delayed diagnosis rates as well as the good long-term survival," says Dr. Giulia Veronesi, lead author of the study and member of IASLC. "However, the workup can still be improved, possibly by tailoring the screening interval to the risk of the individual being screened using a risk evaluation algorithm that will hopefully also include in the near future molecular markers like a microRNA expression signature in serum."


'/>"/>

Contact: Rob Mansheim
rob.mansheim@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Improved identification of war wound infections promises more successful treatment
2. Despite economic blows, infant health has improved among US poor
3. E-cigarette use for quitting smoking is associated with improved success rates
4. Donor livers preserved and improved with room-temperature perfusion system
5. Aspirin use appears linked with improved survival after colon cancer diagnosis
6. MATH, HPV status in HNSCC patients effective markers of improved patient outcome
7. Researchers identify possible explanation for link between exercise & improved prostate cancer outcomes
8. Latest Research Shows Improved Long-Term Memory with Same Caffeine Level as 5-hour ENERGY® Shots
9. Personal health record associated with improved medication adherence
10. CEO of Simply G Media GJ Reynolds Discussed His Launch Of The New and Improved SimplyG.com Website on The BeachLifestyle Radio Show.
11. Improved Method of Securing IV Lines Invented by InventHelp Client (BIR-2159)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... ... 2016 , ... A newly released study has found that ... accuracy of placing precordial electrodes with little cognitive effort and a high degree ... studies have shown that single electrode misplacement is one of the single largest ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... , , ... reach 17.27 billion by 2021, at a CAGR of 5.3% from 2016 ... growing number of obesity cases, increasing government spending on healthcare, and rising ...
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life ... , , ... stakeholders crucial insight into Switzerland ; a country located ... of the world,s most important international health institutions as well as two ... number one ranking globally in terms of ease of doing business and ...
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint ... in discovering and developing targeted kinase medicines for ... from its ongoing Phase 1 trial evaluating BLU-285, ... with advanced systemic mastocytosis (SM). Blueprint Medicines is ... of D816V mutant KIT. Approximately 90 to 95 ...
Breaking Medicine Technology: